Thermo Fisher Acquires Audax-Backed CorEvitas For Over $900M
Portfolio Pulse from Vandana Singh
Thermo Fisher Scientific Inc (NYSE:TMO) has agreed to acquire CorEvitas LLC from Audax Private Equity for $912.5 million in cash. CorEvitas provides regulatory-grade, real-world evidence solutions to pharmaceutical and biotechnology companies. The acquisition is expected to be completed by the end of 2023 and will be immediately accretive to adjusted earnings per share by $0.03 in 2024.
July 06, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Thermo Fisher's acquisition of CorEvitas for $912.5M is expected to boost its earnings per share by $0.03 in 2024. The deal is expected to be completed by the end of 2023.
The acquisition of CorEvitas by Thermo Fisher is a significant move that is expected to boost the company's earnings per share by $0.03 in 2024. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100